Zta has a dual role in the Epstein-Barr virus (EBV) lytic cycle,
acting as a key regulator of EBV lytic gene expression and also being
essential for lytic viral DNA replication. Zta's replication function
is mediated in part through interactions with the core viral
replication proteins. We now show interaction between Zta and the
helicase (BBLF4) and map the binding region to within amino acids (aa)
22 to 86 of the Zta activation domain. In immunofluorescence assays,
green fluorescent protein (GFP)-tagged BBLF4 localized to the cytoplasm
of transfected cells. Cotransfection of Zta resulted in translocation
of BBLF4-GFP into the nucleus indicating interaction between these two
proteins. However, Zta with a deletion of aa 24 to 86 was unable
to mediate nuclear translocation of BBLF4-GFP. Results obtained with
Zta variants carrying deletions across the aa 24 to 86 region indicated
more than one contact site for BBLF4 within this domain, and this was
reinforced by the behavior of the four-point mutant Zta (m22/26,74/75),
which was severely impaired for BBLF4 interaction. Binding of BBLF4 to
Zta was confirmed using GST affinity assays. In both
cotransfection-replication assays and replication assays performed in
EBV-positive P3HR1 cells, the Zta (m22/26,74/75) mutant was replication
defective. In Zta-transfected D98-HR1 cells, replication compartments
could be detected by immunofluorescence staining using anti-BMRF1
monoclonal antibody. Cells transfected with Zta variants that were
defective for helicase binding still formed replication compartments,
but Zta was excluded from these compartments. These experiments reveal
a role for the Zta-helicase interaction in targeting Zta to sites of
viral DNA replication.
 |
INTRODUCTION |
The Epstein-Barr virus (EBV) lytic
regulatory protein Zta (BZLF1, ZEBRA, Z) plays a key role in both
regulation of EBV lytic gene expression and in lytic viral DNA
replication. Zta is related to the Fos/CEBP family of cellular bZIP
transcription factors but contains a unique coiled-coil dimerization
domain that lacks the standard heptad leucine repeat (13, 19,
21). As a consequence, Zta forms homodimers and does not
heterodimerize with the cellular Jun, Fos, and CREB bZIP proteins. Zta
binds to both AP-1 sites and related sequences called Zta response
elements (ZREs) (19, 38, 57). Both DNA binding and Zta
activity are modulated by phosphorylation (7, 31). Zta
activates transcription through stabilization of a TFIIA-TFIIID complex
(17, 37, 40) and by recruiting the CREB-binding protein
CBP (1, 14, 62). CBP and the related p300 possess
intrinsic histone acetylase activity. They stimulate transcription
through acetylation of histones, which leads to chromatin remodeling,
through the acetylation of nonhistone transcription factors and by
serving as a bridging factor between transcription factors and
polymerase II (6, 33, 46, 48).
Two cis-acting regions have been defined as essential
components of the EBV lytic origin of replication, oriLyt (25,
54). One of these comprises the promoter for the BHLF1 open
reading frame which contains four ZREs and the second region, which is located 530 bp distally and does not contain ZREs, is required for
oriLyt replication but not for transcriptional regulation of BHLF1
(8, 47). Mutation of all four of the ZREs in the promoter
proximal region abolished oriLyt replication, indicating the necessity
for Zta binding to this region for origin function (53).
In a complementary approach, examination of the trans-acting EBV proteins needed for replication of an oriLyt containing plasmid in
a Challberg cotransfection assay in EBV-negative cells also revealed an
absolute requirement for Zta. In this assay, oriLyt replication was
dependent on the presence of Zta plus six core replication proteins,
the DNA polymerase (BALF5), polymerase processivity factor (BMRF1),
single-stranded DNA-binding protein (BALF2), helicase (BBLF4), primase
(BSLF1), and the primase-associated factor (BBLF2/3) (20,
52).
Zta is likely to contribute to oriLyt replication through a variety of
mechanisms. Zta induces growth arrest, in part through posttranscriptional p53 stabilization and upregulation of the cyclin-dependent kinase inhibitors p21 and p27 (11, 49).
Unlike the smaller DNA viruses, herpesviruses encode many of the
enzymes necessary for DNA replication, and it may be advantageous for these viruses to replicate their genomes at a time when they are not
competing with cellular DNA replication. The Zta activation domain is
not required for Zta-induced growth arrest (12). Recent work has revealed that incoming viral genomes of adenovirus, simian virus 40 (SV40), herpes simplex virus (HSV), human
cytomegalovirus (HCMV), and Kaposi's sarcoma-associated
herpesvirus (KSHV) accumulate and replicate at promyelocytic
leukemia protein (PML)-associated nuclear bodies called PODs (PML
oncogenic domains) or ND10 (nuclear domain 10) (4, 10, 28, 42,
56, 59). In HSV- and HCMV-infected cells the POD structure is
disrupted prior to lytic DNA replication (3, 32, 43), but
replication compartments were detected in KSHV-infected cells that were
decorated on the periphery with PODs (59). Induction of
lytic replication in EBV-positive D98-HR1 cells revealed a complex
process in which the POD protein Sp100 was dispersed prior to the onset
of DNA replication, but PML dispersion and loss of POD structure was
delayed until after the detection of replicating viral DNA
(9). Zta appears to be the EBV protein that mediates
late-stage dispersion of PODs, and the N terminus of the Zta activation
domain is required for this function (2). The ability of
Zta to disperse PML may be related to competition between Zta and PML
for SUMO-1 modification (2).
Zta may also contribute to origin function through its transcriptional
activity. Transcription factors frequently bind to auxiliary sequences
flanking the minimal origin region where they stimulate replication
efficiency (15, 24, 45) by contributing to the relief of
nucleosomal repression (27, 35, 44). Initial deletion
analyses of the Zta transcriptional activation domain found concurrent
reductions in both the transcription and the replication functions of
Zta (5, 53). However, there were indications that the Zta
transactivation domain might have a role in oriLyt replication beyond
that made by its contribution to transcriptional activation. An oriLyt
plasmid in which the ZRE sites were converted to binding sites for
either human papillomavirus E2 or yeast Gal4 could not be efficiently
replicated by these proteins but was replicated by Zta fusion proteins
targeted to the altered binding sites (53). Further, an
activation domain deletion, Zta(
11-25) that had no negative effects
on transactivation function resulted in a Zta protein that was
replication deficient in cotransfection replication assays
(51).
In herpesvirus-infected cells, lytic viral DNA replication takes place
in globular or kidney-shaped nuclear subdomains that stain for viral
replication proteins (3, 41, 52, 58, 59, 66). Replication
compartment formation has not been extensively examined in EBV-infected
cells but Zta and BMRF1 were shown to colocalize in replication
compartments formed after induction of the lytic cycle in EBV-infected
Akata cells (55). In the present study we examined the
interaction between the EBV helicase BBLF4 and Zta. The BBLF4
interaction site mapped to the amino acid (aa) 22 to 86 segment of the
Zta transactivation domain adjacent to the interaction site for the
BSLF1-BBLF2/3 primase subcomplex, further illustrating the complexity
of contacts made by the core replication proteins. Zta mutants that
were defective for helicase interaction failed to efficiently associate
with replication compartments in Zta-transfected D98-HR1 cells,
providing evidence for an additional role for the helicase in the
intranuclear targeting of Zta.
 |
MATERIALS AND METHODS |
Plasmid constructions.
A 750-bp BglII fragment
containing the green fluorescent protein (GFP) coding sequences was
obtained by introducing a 10-mer BglII linker into the
NheI site of pEGFP-C1 (Clontech, Inc.) and cleaving with
BglII. BBLF4-GFP was constructed by ligating the 750 bp
fragment into BclI-cleaved pRTS28 (23). The Zta
inserts from the plasmids pPL228 (39), pZQ239, and
pZBS
39-45 (obtained from P. Lieberman) were transferred as
EcoRI or BamHI fragments, respectively, into the
appropriate sites of the SG5 vector (Stratagene) to generate Zta
24-86, Zta
3-39, and Zta
39-45 eukaryotic expression plasmids. Zta
61-81 was constructed by PCR amplification of Zta aa
1 to 60 using the primers 5'-CAGTGGATCCTAATGATGGACCCAAACTCG and 5'-GCTAGCGGCCGCTGGCCTTGTGGCAGA, and Zta aa 82 to
245 was constructed using the primers
5'-GCTAGCGGCCGCCTCCTGAGAATGCTTAT and
5'-GCTAGGATCCTTACTTGTCATCGTCGTCC. The
NotI-cleaved PCR products were ligated, and the Zta aa 1 to 60 plus 82-to-245 fragment was purified and ligated into the
BamHI site of the SG5 vector. A pPL230 (51)
EcoRI fragment was ligated into pGH416 to create the
glutathione S-transferase (GST)-Zta
94-140 fusion protein
expression plasmid. GST-Zta(wt)(pDH237), GST-Zta(26-133)(pDH279), and
GST-Zta(1-133)(pDH245) have been described elsewhere
(23), as have the oriLyt-chloramphenicol acetyltransferase
(CAT) reporter, pDH123, and the expression plasmid for Zta(wt), pRTS21,
and Zta(
2-25). (51). The Zta(m22/24,74/75) and
GST-Zta(22/24,74/75) plasmids were a gift from Paul M. Lieberman (40).
Immunofluorescence assays.
Vero cells were seeded at 8 × 104 cells per well in two-well slide chambers. Cells
were transfected with a maximum of 3 µg of DNA by the calcium
phosphate procedure. After transfection, cells were incubated in
Dulbecco modified Eagle medium plus 10% fetal bovine serum for 16 h at
35°C in 3% CO2, followed by a medium change and a
further 24-h incubation. When appropriate, bromodeoxyuridine (BrdU) was
added to the culture medium at a final concentration of 10 µM for 45 min before fixation. Cells were washed in phosphate-buffered saline
(PBS; 0.144 g of KH2PO4, 9.0 g of NaCl,
and 0.795 g of Na2HPO4 · 7H2O per liter), fixed with 1% paraformaldehyde in PBS for
10 min at room temperature, and permeabilized for 20 min on ice in
0.2% Triton X-100 in PBS. For BrdU staining, pulse-labeled cells were
incubated with 4 N HCl for 10 min at room temperature in order to
expose incorporated BrdU residues and then washed in PBS three times
for 5 min each time before permeabilization. Cells were incubated with
primary antibody for 60 min at 37°C and with secondary antibody at
37°C for 30 min. The antibodies used were anti-BMRF1 monoclonal
antibody (1:200; ABI Advanced Biotechnologies, Inc., Columbia, Md.),
anti-BZLF1 polyclonal antibody (1:800; a gift of Marie Hardwick, Johns
Hopkins School of Hygiene and Public Health), and sheep anti-BrdU
antibody (1:200; Fitzerald Industries International, Inc., Concord,
Mass.), fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse
immunoglobulin G (IgG; 1:200; Cappel Organon Teknika, Durham, N.C.),
FITC-conjugated donkey anti-rabbit IgG (1:200), rhodamine-conjugated
donkey anti-mouse immunoglobulin (1:200) and anti-rabbit immunoglobulin
(1:200), and rabbit anti-sheep IgG (1:200; Chemicon, Temecula, Calif.).
CAT assay.
Hela cells were plated in six-well cluster dishes
at 2 × 105 cells per well 16 h before
transfection, with a medium change 4 h before transfection. Cells
were transfected by calcium phosphate precipitation with the oriLyt-CAT
reporter (pDH123, 1 µg) and Zta or Zta variants. Vector
SG5 DNA was used to equalize the amount of DNA in each transfection to
5 µg. Each experiment was repeated at least two times. CAT assays
were performed as previously described (26). Total protein
was measured using the BCA Protein Assay Reagent (Pierce, Rockford,
Ill.), and equal amounts of protein were analyzed for CAT activity.
GST-protein affinity assay.
GST and GST-Zta fusion proteins
were induced by growth in medium containing 100 µM
isopropyl-
-D-thiogalactopyranoside (IPTG) for 3 h
at 30°C. Pelleted bacteria were resuspended in binding buffer (50 mM
Tris-HCl [pH 7.9], 100 mM NaCl, 5 mM MgCl2, 0.5 mM EDTA,
2 mM dithiothreitol [DTT], 0.2% Nonidet P-40) and sonicated. Cell
debris was removed by centrifugation at 10,000 × g for
10 min. The supernatant was incubated with glutathione agarose beads (Sigma, St. Louis, Mo.) at 4°C overnight, followed by three washes in
binding buffer. The amount of protein bound to the beads was determined
by Coomassie brilliant blue staining of protein separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Equal
amounts of each GST protein were used in the affinity assays.
293T cells in 100-mm dishes were transfected with a maximum of 15 µg
per dish of DNA, and cells were harvested 40 h after transfection.
Cells were lysed in 2.2 ml of lysis buffer (50 mM Tris-HCl [pH 7.4],
100 mM NaCl, 0.5 mM MgCl2, 1 mM EDTA, 2 mM DTT, and 0.2%
Nonidet P-40). Cell extract was incubated with the GST fusion
protein-glutathione agarose beads overnight at 4°C, after which the
complex was washed five times in binding buffer. The complex was
dissociated from the beads by boiling for 5 min in 2× SDS-PAGE loading
buffer (2% SDS, 10% glycerol, 100 mM DTT, 60 mM Tris [pH 6.8],
0.02% bromophenol blue), and the proteins were separated by SDS-PAGE
on a 10% gel. Proteins were transferred to a nitrocellulose membrane
(Bio-Rad, Hercules, Calif.), and BBLF4-GFP and GFP proteins were
detected by incubation with an anti-GFP monoclonal antibody (1:5,000;
Clontech), followed by visualization using enhanced chemiluminescence
(Amersham Life Science, Buckinghamshire, England).
DNA replication assays.
The DNA transfection-replication
assay was performed using a modification of the previously described
protocol (51, 52). Briefly, 1.5 × 106
Vero cells per 100-mm dish were transfected with 10 µg of
pEF52(ori-Lyt) DNA, 1.6 µg of Zta expression plasmid, and 0.8 µg of
expression plasmids for each of the six core replication proteins, as
well as Mta and Rta. At 80 h after the posttransfection medium
change, the cell monolayer was washed twice with PBS and scraped into 4 ml of 40 mM Tris-HCl (pH 7.5), 1 mM EDTA, and 150 mM NaCl. The cells
were then pelleted and lysed in 2 ml of lysis buffer (10 mM Tris-HCl
[pH 8.0], 10 mM EDTA, 2% SDS, 100 µg of proteinase K per ml).
After overnight incubation at 37°C, the samples were diluted to 4 ml
with Tris-EDTA (pH 8.0); extracted with phenol, phenol-chloroform, and
chloroform; and ethanol precipitated after the addition of sodium
acetate (pH 5.2) to a final concentration of 0.3 M. The DNA pellets
were resuspended in 450 µl of distilled H2O,
treated with 100 µg of RNase A per ml, ethanol precipitated, and
resuspended in 300 µl of H2O. Then, 10 µg of
extracted cellular DNA was digested overnight with 30 U of
DpnI at 37°C. Replicated DNA was detected by PCR
amplification using oligonucleotide primers specific for pBR322 DNA.
The primers 5'-GAAGCCAGTTACCTTCGG and 5'-GCAGGACCACTTCTGCG amplified a 510-bp fragment containing
seven DpnI restriction sites, while the primers
5'-CTGTGGAACACCTACATCTG and 5'-AGATGTCTGCCTGTTCATCC
amplified a 330-bp control fragment that lacked DpnI
sites. The products were visualized by electrophoresis on a 1.2%
agarose gel containing 500 ng of ethidium bromide per ml.
In the induction-replication assay, EBV-infected P3HR-1 cells were
transfected with Zta or Zta variants by electroporation (300 V;
capacitance, 950 µF; DNA, 2 µg). Total cellular DNA was extracted
as described above, and an equal amount of the DNA as determined by
spectrophotometry and ethidium bromide fluorescence quantitation was
digested with BamHI. The cellular DNA was resolved by
electrophoresis on a 1.0% agarose gel at 80 V for 6 h. After treatment of the gel at 20°C for 45 min in 1.5 mol of NaCl and 0.5 mol of NaOH per liter and incubation in 1.5 mol of NaCl and 1 mol of
Tris-HCl (pH 7.4) per liter for 15 min, the agarose gel was then
transferred to a nitrocellulose membrane in the presence of 10× SSC
(1.5 M NaCl plus 0.15 M sodium citrate) for 16 to 20 h. After the
membrane was dried completely at 20°C, the DNA was irreversibly
cross-linked by UV radiation (Stratalinker; Stratagene). For
hybridization, the membrane was incubated for 3 h at 65°C in 15 ml of buffer consisting of 6× SSPE (900 mM NaCl, 60 mM
Na2HPO4, 6 mM Na2EDTA), 5×
Denhardt solution, 0.5% SDS, and 91 µg of calf thymus DNA (Sigma
Chemical Co., St. Louis, Mo.) per ml. Approximately 25 ng of a
gel-purified EBV genomic EcoRI-Dhet fragment was
radiolabeled with [
-32P]dCTP by random priming to a
specific activity of 108 cpm/µg (Boehringer
Mannheim-Roche Kit). The membrane was then incubated at 65°C with
106 cpm of denatured radiolabeled EcoRI-Dhet
probe DNA per ml in fresh hybridization buffer. Following hybridization
for 16 h, the membrane was washed in 2× SSC-0.5% SDS at room
temperature for 5 min, in 2× SSC-0.1% SDS for 5 min, and in 0.1×
SSC-0.5% SDS at 37°C for 30 min and then again at 65°C for 45 min. The membrane was exposed to Kodak XAR5 film for 12 h at
80°C using an intensifying screen.
 |
RESULTS |
Zta interaction with the EBV helicase, BBLF4.
The EBV
helicase, BBLF4, has previously been shown to localize to the cytoplasm
of transfected cells (23). Cotransfection with Zta was
found to result in nuclear translocation of BBLF4, suggesting an
interaction between these two proteins (23). A BBLF4-GFP
expression vector was generated to further characterize this
interaction. BBLF4-GFP was transfected into Vero cells alone or with
the series of Zta expression plasmids shown in Fig.
1A and the intracellular localization of
BBLF4-GFP was determined by fluorescence microscopy (Fig. 1B). In
transfected cells, BBLF4-GFP showed a cytoplasmic distribution.
This localization was converted to nuclear when BBLF4-GFP was
cotransfected with wild-type Zta. However, Zta(
24-86) was
ineffective at mediating nuclear localization of BBLF4-GFP. Deletions
were created across the aa 24 to 86 region in an attempt to further
define the sequences required for BBLF4 binding. Deletion of either the
front portion of this domain [Zta(
3-69)] or the back portion
[Zta(
61-81)] had a similar effect. In each case, cotransfection
with BBLF4-GFP led to the detection of nuclear BBLF4-GFP, although the
efficiency of nuclear translocation was reduced, and cytoplasmic
BBLF4-GFP was also detected in a significant proportion of the cells
(Fig. 1B; Table 1). Changing the spacing between the boundaries of the domain by introducing a small 6-aa deletion in the central region [Zta(
39-45)] also had the effect of reducing the effectiveness of the interaction as measured by BBLF4-GFP nuclear localization (Fig. 1B; Table 1). These results suggested that BBLF4 might make contacts within each half of the aa 24 to 86 region of Zta. In support of this conclusion, a mutant [Zta(m22/26,74/75)] that carried a pair of mutations at each margin of the aa 24 to 86 region was severely impaired for nuclear
translocation of BBLF4-GFP (Fig. 1B) (Table 1).


View larger version (42K):
[in this window]
[in a new window]
|
FIG. 1.
Effect of cotransfected Zta on the intracellular
localization of BBLF4-GFP. (A) Diagrammatic representation of the Zta
plasmids used in the cotransfection assays. (B) Representative
photomicrographs of Vero cells transfected with BBLF4-GFP either alone
or in the presence of the indicated wt or mutant Zta plasmids. The
intracellular localization of BBLF4-GFP was determined by fluorescence
microscopy.
|
|
Mapping the interaction domain for BBLF4-GFP using GST affinity
assays.
To provide additional evidence that Zta binds to BBLF4 and
that the aa 22 to 86 region of Zta was required for the interaction. GST affinity assays were performed using the GST-Zta constructions illustrated in Fig. 2A. Extracts from
293T cells transfected with either BBLF4-GFP or a GFP control vector
were incubated with glutathione beads containing equal amounts of the
different GST-Zta proteins. The relative amounts of GST-Zta proteins
used were determined by Coomassie brilliant blue staining of the
SDS-PAGE-separated proteins (Fig. 2B, lower panel). Western blot
analysis to detect protein binding to the GST-Zta proteins was
performed using anti-GFP antibody and a chemiluminescence visualization
procedure. Wild-type GST-Zta bound BBLF4-GFP, as did the GST-Zta
activation domain construction, Zta(1-133) (Fig. 2B, upper panel). Zta
carrying an internal deletion of the carboxy-terminal region of the
activation domain, GST-Zta(
94-140), also bound BBLF4-GFP, although
with slightly reduced affinity (Fig. 2B, upper panel). Neither
GST-Zta(26-133) nor Zta(m22/26,74/75) bound BBLF4-GFP (Fig. 2B, upper
panel), again emphasizing the importance of sequences in the aa 22 to 26 and aa 74 to 86 regions of Zta for BBLF4 binding. There was no
binding of BBLF4-GFP to GST alone (Fig. 2B, upper panel), nor did the
control GFP protein bind to any of the GST constructions (Fig. 2B,
middle panel).


View larger version (71K):
[in this window]
[in a new window]
|
FIG. 2.
Binding of BBLF4-GFP to GST-Zta constructions. (A)
Diagrammatic representation of the GST-Zta constructions used. (B,
upper panel) GST affinity assay in which a BBLF4-GFP transfected 293T
cell extract was incubated with equal amounts of GST or the indicated
GST-Zta proteins bound to glutathione beads. Bound protein was detected
by Western blot analysis using anti-GFP antibody and a
chemiluminescence visualization procedure. A total of 5 µl
of extract was directly loaded in the extract lane. (Middle panel) GST
affinity assay performed as described above using an extract of 293T
cells transfected with control vector expressing GFP. (Lower panel)
SDS-polyacrylamide gel stained with Coomassie brilliant blue showing
the GST and GST-Zta proteins used in the binding assays presented in
the upper and middle panels.
|
|
Zta(m22/26,74/75) is defective for DNA replication.
To examine
the functional consequences of loss of BBLF4 binding, Zta(m22/26,74/75)
was tested for its ability to support lytic EBV DNA replication. We
first used a PCR-based cotransfection-replication assay to compare the
replication function of wild-type Zta with that of the Zta mutant
Zta(m22/26,74/75). Vero cells were transfected with an oriLyt
containing plasmid, along with expression plasmids for the six core EBV
replication proteins, Rta and Mta plus either wild-type Zta,
Zta(m22/26,74/75) or vector DNA. At 80 h posttransfection the
cells were harvested, the DNA was extracted, and the concentration was
determined by absorbance at 260 nm. Equal amounts of DNA from each
transfection were either digested overnight with DpnI or were left untreated. Segments of the oriLyt plasmid DNA backbone were
then amplified in a PCR reaction using two different sets of primers.
The first set of primers amplified a 510-bp segment of the oriLyt
plasmid backbone. This 510-bp region contains seven DpnI
sites. The bacterially grown oriLyt plasmid DNA that is transfected into the cells is methylated and will be cleaved by DpnI,
whereas DNA that has been replicated in the transfected mammalian cells will no longer carry the bacterially imposed methylation pattern and
will not be cleaved. Thus, after DpnI digestion of the DNA, the 510-bp fragment should be readily amplifiable only from cells in
which Zta has been able to support oriLyt DNA replication. On the other
hand, in the absence of DpnI digestion the 510-bp fragment
should be equally amplifiable from each of the DNA samples. A second
set of PCR primers was used to control for any nonspecific effects of
DpnI digestion. This primer pair amplified a 330-bp segment
of the oriLyt plasmid backbone that does not contain any DpnI sites. In this case, the DpnI-digested DNA
samples should be equally amplifiable regardless of whether or not the
oriLyt plasmid had been replicated.
An example of the PCR cotransfection-replication assay is shown in Fig.
3. When DpnI-digested DNA was
used as the template for the PCR amplification, the 510-bp fragment was
readily amplified from Vero cells that had been transfected with
wild-type Zta (Fig. 3, lanes 4 and 5) but was inefficiently amplified
from Vero cells that had been transfected with either vector DNA (Fig.
3, lanes 2 and 3) or Zta(m22/26,74/75) (Fig. 3, lanes 6 and 7). In the absence of DpnI digestion (Fig. 3, lanes 9 to 11), the
510-bp PCR fragment was amplified equally from each of the three
transfected DNA samples, indicating that the lack of amplification seen
in lanes 6 and 7 was linked to DpnI cleavage of the template
and not to any inherent inability to amplify the 510-bp PCR fragment from the DNA of Zta(m22/26,74/75)-transfected cells. Similarly, the
310-bp control PCR fragment that lacked DpnI cleavage sites was equally amplified from each of the three DpnI-digested
DNA samples (Fig. 3, lanes 13 to 15).

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 3.
Zta(m22/26,74/75) is unable to replicate an oriLyt
plasmid. Ethidium bromide-stained gel of electrophoretically separated
PCR-amplified fragments of the non-EBV backbone sequences of the oriLyt
plasmid pEF52. Vero cells were transfected with pEF52, expression
plasmids for the six core replication genes, Mta and Rta plus either
control vector DNA or expression plasmids for wild-type Zta or
Zta(m22/26,74/75). DNA was isolated from the transfected cells, and
segments of the oriLyt plasmid backbone were amplified by PCR either
before or after digestion of the DNA with the methylation-sensitive
restriction enzyme DpnI. The test primers amplify a 510-bp
fragment that contains seven DpnI sites, while the control
primers amplify a 330-bp fragment that does not contain any
DpnI sites. After DpnI digestion of the
transfected cell DNA, the 510-bp fragment should only be amplifiable if
the input DNA has been replicated in the transfected cells. Lane 1, marker DNA ladder; lanes 2 to 8, DpnI-digested DNA amplified
with the test primers; lanes 9 to 12, undigested DNA amplified with the
test primers; lanes 13 to 17, DpnI-digested DNA amplified
with the control primers. Plasmid DNA, the PCR reaction was performed
directly on the input plasmid DNA; water, no DNA added.
|
|
The results of the cotransfection-replication assay suggested that the
Zta(m22/26,74/75) mutant that was impaired for binding to BBLF4 was
also impaired for oriLyt DNA replication. We next evaluated the ability
of Zta(m22/26,74/75) and Zta(
24-86) to replicate the endogenous EBV
genomes in P3HR1 cells. Transfection of wild-type Zta into P3HR1 cells
leads to induction of the lytic cycle. The ability to evaluate Zta
mutants in a setting in which endogenous EBV genomes are present
derives from the observation that exogenous Zta activates the full
pattern of lytic gene expression with the key exception of the
expression of endogenous Zta (30). The presence of
low-affinity Zta binding sites overlapping the Zta mRNA start site
(36) may be responsible, since binding of Zta to these
sites in situations of Zta overexpression would result in
transcriptional occlusion. The amplification of linear viral DNA in
Zta-transfected P3HR1 cells can be assessed by Southern blotting. The
linear EBV genome is bounded by 500-bp terminal repeats. The numbers of
repeats at each end vary and hence restriction fragments such as
BamHI-Nhet and EcoRI-Dhet that encompass the termini display size heterogeneity (Fig.
4A). The induction of DNA replication of
the endogenous viral genomes in P3HR1 was examined by isolating DNA
from transfected cells, digesting the DNA with BamHI, and
probing Southern blots of the separated DNA fragments with
32P-labeled EcoRI-Dhet to determine the relative
amounts of the BamHI-A and BamHI-Nhet fragments.
The BamHI-A fragment serves as a marker for the relative
number of genomes in the cell, while the BamHI-Nhet fragment
is diagnostic for linear EBV genomes.

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 4.
Zta(m22/26,74/75) and Zta( 24-86) are unable to
replicate endogenous P3HR1 genomes. (A) Schematic representation of the
righthand end of the EBV genome showing the relative locations of the
terminal EcoRI and BamHI restriction fragments.
TR, terminal repeats. (B) Southern blot of DNA isolated from P3HR1
cells electroporated with the indicated plasmids. After cleavage with
BamHI, the electrophoretically separated DNA fragments were
transferred to a nitrocellulose membrane and probed with a
32P-labeled EcoRI-Dhet probe. As indicated by
the increase in the amount of the BamHI-Nhet fragment,
linear EBV genomes were efficiently amplified only in wild-type
Zta-transfected cells. Lanes 1 to 5, DNA isolated from electroporated
P3HR1 cells; lane 6, cosmid 302-21 DNA digested with
BamHI.
|
|
The concentration of the DNA isolated from transfected cells was
measured by the absorbance at 260 nm and checked by gel electrophoresis and ethidium bromide staining for DNA quality. Equal amounts of each
sample were then subjected to restriction enzyme digestion and analyzed
by Southern blotting. The DNA isolated after transfection of wild-type
Zta into P3HR1 cells showed greatly increased levels of both the
BamHI-A and BamHI-Nhet fragments compared to the
levels seen in the control vector transfected cells (Fig. 4B).
Zta(
2-25) had previously been found to be replication defective
(51) and, as expected, there was no increase in
BamHI-Nhet DNA in P3HR1 cells transfected with Zta(
2-25)
(Fig. 4B). There was only a marginal increase in BamHI-Nhet
DNA in cells transfected with Zta(m22/26,74/75) (Fig. 4B).
Zta(
24-86) was also unable to support replication of the endogenous
genomes in P3HR1 cells (Fig. 4B). Thus, the two mutants that showed
loss of BBLF4 (helicase) binding were both replication defective in
this assay.
Zta(m22/26,74/75) and Zta(
24-86) retain transactivation
activity.
Replication assays performed in P3HR1 or D98-HR1 cells
are dependent on the expression of the core EBV replication proteins from the endogenous genomes. The Zta(m22/26,74/75) and Zta(
24-86) mutations lie within the transcriptional activation domain of Zta. The
activation domain has been shown to have a modular construction, and
deletion of any one segment reduces, but does not eliminate, transcriptional activity (16, 37). The behavior of the
Zta(m22/24,74/75) and Zta(
24-86) mutants compared to
wild-type Zta is illustrated in the reporter assay in Fig.
5. At low concentrations of transfected effector DNA, the Zta(m22/24,74/75) and Zta (
24-86) mutants
were severely impaired in their ability to activate expression from an
oriLytp-CAT reporter relative to wild-type Zta. However, the deficiency
could be partially compensated for by increasing the dose of input DNA.
This was not the case for wild-type Zta, which gave maximal
transactivation responses at low levels of input plasmid DNA. The
wild-type and Zta(m22/24,74/75) and Zta(
24-86) mutants
express comparable levels of Zta protein in transfected cells as
measured by Western blotting.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 5.
CAT reporter assay comparing transactivation activity of
wild-type Zta and the Zta(m22/24,74/75) and Zta( 24-86) mutants.
HeLa cells were transfected with an oriLytp-CAT reporter (1 µg) and increasing amounts of expression vectors for
wild-type or mutant Zta. Cells were harvested for determination of CAT
activity 40 h after transfection.
|
|
Since Zta-induced replication in P3HR1 or D98-HR1 cells requires the
induction of EBV replication gene expression from endogenous genomes
rather than transfected DNA, the effect of the Zta(m22/26,74/75) and
Zta(
24-86) mutations on the induction of one of the core replication proteins, the BMRF1 polymerase processivity factor, was
also examined by immunofluorescence analyses. Untransfected D98-HR1
rarely express BMRF1. Transfection of wild-type Zta resulted in the
induction of BMRF1 in approximately 7% of the cells. In double-staining experiments, all BMRF1-positive cells were also Zta
positive (data not shown). D98-HR1 transfected with either Zta(m22/26,74/75) or Zta(
24-86) showed induction of BMRF1
expression that was only marginally reduced from that seen with
wild-type Zta (Fig. 6). Thus, the
inability of Zta(m22/26,74/75) and Zta(
24-86) to support
replication of the endogenous genomes in D98-HR1 cells is likely to be
a true replication deficit and not due solely to transcriptional
impairment.

View larger version (89K):
[in this window]
[in a new window]
|
FIG. 6.
Zta(m22/26,74/75) and Zta( 24-86) activate expression
of BMRF1 from endogenous EBV genomes. Immunofluorescence assay
performed on D98-HR1 cells before and after transfection with the
indicated Zta plasmids. Cells were stained with anti-BMRF1 (polymerase
processivity factor) monoclonal antibody and FITC-conjugated secondary
antibody.
|
|
Zta(m22/26,74/75) and Zta(
24-86) fail to target efficiently to
replication compartments.
We wished to address the requirements
for DNA replication compartment formation in transfected D98-HR1 cells.
Replication compartments are visible in immunofluorescence assays as
large intranuclear bodies. Replication compartments were detected in D98-HR1 cells transfected with wild-type Zta by staining for BMRF1 (polymerase processivity factor) (Fig.
7). These structures were shown to
represent functional replication compartments by incubating the cells
with BrdU and double staining for sites of BrdU incorporation with
anti-BrdU antibody. The BrdU staining colocalized with BMRF1 in
the intranuclear bodies (Fig. 7).

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 7.
Demonstration of replication compartment formation in
D98-HR1 cells. Immunofluorescence assay performed on D98-HR1 cells that
were transfected with wild-type Zta and incubated with BrdU 45 min
prior to fixation. Cells were double stained for the polymerase
processivity factor BMRF1 (a and d) using anti-BMRF1 monoclonal
antibody and FITC-conjugated anti-mouse immunoglobulin secondary
antibody and for BrdU (b and e) using anti-BrdU sheep antibody and
rhodamine-conjugated anti-sheep immunoglobulin as the secondary
antibody. Merge, overlays of the FITC and rhodamine images (c and f).
Replication bodies are visible that double stain for BrdU incorporation
and the presence of viral replication proteins, as exemplified by
BMRF1.
|
|
Replication compartments were also detected in D98-HR1 cells
transfected with Zta(m22/26,74/75) or Zta(
24-86) and stained with
anti-BMRF1 antibody (Fig. 8). This
reinforces the belief that there is not a profound deficit in induction
of early replication proteins in Zta(m22/26,74/75)- and
Zta(
24-86)-transfected cells. However, double staining of these
cells for Zta revealed a distinct difference in Zta distribution (Fig.
8). Whereas wild-type Zta was localized predominantly within the
replication compartments, Zta(m22/26,74/75) and Zta(
24-86) were
excluded from the replication compartments and were instead distributed
throughout the remainder of the nucleoplasm. These experiments suggest
that BBLF4 binding is necessary for Zta to be efficiently incorporated
into replication compartments. The replication deficit of the
Zta(m22/26,74/75) and Zta(
24-86) mutants is therefore linked to the
inability of these Zta mutants to physically associate with sites of
viral DNA replication.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 8.
Zta(m22/26,74/75) and Zta( 24-86) fail to associate
with replication compartments. An immunofluorescence assay was
performed on D98-HR1 cells transfected with expression vectors for
wild-type or mutant Zta. Cells were stained for BMRF1 using anti-BMRF1
monoclonal antibody and for Zta using rabbit anti-Zta antiserum.
Wild-type Zta colocalized with the replication compartments, whereas
the two Zta mutants were excluded from these bodies. Merge, overlays of
the FITC and rhodamine images.
|
|
 |
DISCUSSION |
A central role for Zta in lytic EBV DNA replication lies with the
recruitment and assembly of a replication complex on oriLyt. The
interactions that have been described between Zta and the core
replication proteins and between individual viral replication proteins
indicate that complex formation relies on multiple contact points among
the participating proteins. The helicase (BBLF4), primase (BSLF1), and
primase-associated factor (BBLF2/3) form a tripartite complex, as do
the equivalent proteins in HSV (18). In DNA-transfected
cells in which changes in intracellular localization of the proteins
were used as a measure of interaction, BSLF1 was shown to interact with
BBLF2/3, and evidence for a tripartite complex was also presented
(23). These interactions were confirmed in
immunoprecipitation assays using baculovirus-expressed proteins, with
additional evidence provided for separate contacts by both BSLF1 and
BBLF2/3 with BBLF4 (60). We had previously mapped the site
of interaction of the primase subcomplex (BSLF1-BBLF2/3) with Zta to
the N terminus of the Zta activation between Zta aa 11 and 25 (23). We now show that BBLF4 interacts with the adjacent region of Zta between aa 22 and 86. The helicase-primase complex has
also been found to interact with polymerase (BALF5) (22). Polymerase interacts with the polymerase processivity factor (BMRF1) (29, 34), which in turn interacts with the bZIP domain of Zta (65). The single-stranded DNA-binding protein BALF2
has also been found to contact the BALF5-BMRF1 proteins
(61). Thus, direct contacts on Zta are made by two of the
proteins of the helicase-primase complex (BBLF2/3 and BBLF4) and by
BMRF1, and the other core replication proteins appear to be tethered by
interactions to one or more of these three proteins.
The possibility of additional tethering of the replication complex to
oriLyt by cellular transcription factors was raised by the observation
that cotransfected BMRF1 activated transcription from BHLF1 oriLyt
promoter-reporter constructions and that the sequences required for
this activation mapped to the essential promoter distal replication
domain (63, 64). A yeast one-hybrid screen identified Sp1
and ZBP-89 as cellular transcription factors that bound to the
essential promoter distal domain of oriLyt, and these proteins proved
to also interact with BMRF1 and BALF5 (7). Thus, multiple
protein-protein interactions between individual members of the virally
encoded replication complex and between this complex and the DNA-bound
Zta and cellular Spl and ZBP-89 transcription factors contribute to the
origin tethering of the replication complex.
The mapping of the helicase interaction region to aa 22 to 86 within
the Zta activation domain raises questions about the relationship
between Zta's transcription and replication functions. The
Zta(m22/26,74/75) mutant that lost interaction with BBLF4 also shows
some impairment in transactivation function. Zta(m22/26,74/75) was
significantly impaired for activation of the BHLF1(oriLyt) promoter in
in vitro transcription assays but showed no deficit on an artificial
promoter containing seven upstream ZREs (40). In
transfection assays the Zta(m22/26,74/75) mutant was less effective in
activating the BHLF1 promoter, with the deficit being partially compensated for by increasing the amount of transfected
Zta(m22/26,74/75) (40) (Fig. 5). Analysis of the
underlying nature of the deficit in Zta(m22/26,74/75) function revealed
that this mutant had a reduced ability to stimulate the formation of a
stable TFIID-TFILA complex (40) and also was impaired in
its ability to recruit the coactivator CBP to Zta (14).
The loss of interaction with CBP correlated with a reduced ability to
detect Zta-mediated acetylation of histones. The Zta transactivation
domain appears to have a modular structure, in that the loss of
individual segments can be compensated for by increasing the number of
Zta binding sites on the promoter or increasing the copy number of the
other domains (16). It seems likely that the contacts made
by the coactivators, basal transcription factors, and TAFs
(37) are just as complex as those made by the replication
proteins. However, the apparent overlap of the binding region for the
helicase with that for CBP raises the possibility that individual
DNA-bound Zta dimers may be capable of interacting with either a
transcriptional complex or a replication complex but not both
simultaneously. If such were the case, this might explain the
requirement for multiple Zta binding sites within the origin. oriLyt of
the EBV-related baboon virus herpesvirus papio is essentially identical
in structure to EBV oriLyt and also contains multiple Zta binding sites
(50).
Zta(m22/26,74/75) was defective for oriLyt DNA replication in a
cotransfection replication assay and was similarly unable to induce
replication of the endogenous genomes in P3HR1 cells. However,
structures resembling replication compartments were detected in D98-HR1
cells transfected with this Zta mutant. We observed that
Zta(m22/26,74/75) was excluded from the replication compartments and
concluded that this inability to localize to the sites of DNA
replication was a contributing factor in the DNA replication deficit
displayed by Zta(m22/26, 74/75). This Zta mutant is also deficient for
helicase interaction, and the implication is that the helicase targets
Zta to the replication compartments. The formation of replication
compartment-like structures in D98-HR1 cells transfected with
Zta(m22/26,74/75) also implies that replication compartment formation
in EBV does not require the presence of Zta or an active origin of
replication. In cells transfected with the HSV replication machinery,
replication compartment formation was found to be independent of the
origin binding protein UL9 or an origin containing plasmid, and a
similar observation was made for KSHV, where transfection of plasmids
encoding the six core replication proteins was sufficient to allow the
formation of replication compartments (41, 58, 59, 66). In
contrast, the formation of CMV replication compartments in transfected
cells required the presence of an oriLyt plasmid and both ancillary and
core replication proteins (52).
Zta(
24-86), which is also defective for helicase interaction, was
unable to induce replication of the endogenous genomes in P3HR1 cells
and was also not associated with replication compartments in D98-HR1
cells. Previously, Zta(
25-86) had been found to replicate an
oriLyt-containing plasmid in a cotransfection-replication assay (51). A differential ability to replicate a transfected
oriLyt plasmid but not endogenous EBV genomes was also observed with a
Zta aa 200 mutation in studies of Zta-BMRF1 interaction
(65). The reason for the discrepancy between the two
assays is not known but, given the functions mediated by the aa 24 to
86 region of Zta, it is possible to speculate. First, BBLF4 forms a
tripartite complex with BSLF1 and BBLF2/3. These latter proteins bind
to the aa 11 to 25 segment of Zta and can bind to Zta(
24-86). In the presence of high concentrations of the proteins in transfected cells, it seems likely that BBLF4 could be tethered to Zta indirectly through the helicase subcomplex and hence permit Zta to be targeted to
replication foci in the normal manner. A second difference between the
assays is the presence of oriLyt on a transfected plasmid versus the
endogenous and presumably more extensively nucleosome-associated oriLyt
present within the episomal EBV genomes. This region of Zta is also
involved in the recruitment of CBP, which has intrinsic histone
acetylase activity. Ineffective histone acetylation and clearance from
the DNA is likely to be a greater handicap for replication of the
endogenous genomes than for transfected DNA. The complex nature of the
interactions involved in Zta's transcriptional and replication
functions has made it difficult to tease apart the contributions
of individual domains of the Zta protein. This is exemplified by the aa
22 to 86 domain, where protein-protein interactions mediating
replication complex formation, replication compartment targeting, and
nucleosome clearance all contribute to oriLyt DNA replication.
This work was funded by Public Health Service grant CA30356 to
S.D.H. F.Y.W. was partially supported by the Anti-Cancer Drug Development Training Program (T32 CA09243).
| 1.
|
Adamson, A. L., and S. Kenney.
1999.
The Epstein-Barr virus BZLF1 protein interacts physically and functionally with the histone acetylase CREB-binding protein.
J. Virol.
73:6551-6558[Abstract/Free Full Text].
|
| 2.
|
Adamson, A. L., and S. Kenney.
2001.
Epstein-Barr Virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies.
J. Virol.
75:2388-2399[Abstract/Free Full Text].
|
| 3.
|
Ahn, J. H., and G. S. Hayward.
1997.
The major immediate-early proteins IE1 and IE2 of human cytomegalovirus colocalize with and disrupt PML-associated nuclear bodies at very early times in infected permissive cells.
J. Virol.
71:4599-4613[Abstract].
|
| 4.
|
Ahn, J. H.,
W. J. Jang, and G. S. Hayward.
1999.
The human cytomegalovirus IE2 and UL112-113 proteins accumulate in viral DNA replication compartments that initiate from the periphery of promyelocytic leukemia protein-associated nuclear bodies (PODs or ND10).
J. Virol.
73:10458-10471[Abstract/Free Full Text].
|
| 5.
|
Askovic, S., and R. Baumann.
1997.
Activation domain requirements for disruption of Epstein-Barr virus latency by ZEBRA.
J. Virol.
71:6547-6554[Abstract].
|
| 6.
|
Bannister, A. J., and T. Kouzarides.
1996.
The CBP co-activator is a histone acetyltransferase.
Nature
384:641-643[CrossRef][Medline].
|
| 7.
|
Baumann, M.,
R. Feederle,
E. Kremmer, and W. Hammerschmidt.
1999.
Cellular transcription factors recruit viral replication proteins to activate the Epstein-Barr virus origin of lytic DNA replication, oriLyt.
EMBO J.
18:6095-6105[CrossRef][Medline].
|
| 8.
|
Baumann, M.,
H. Mischak,
S. Dammeier,
W. Kolch,
O. Gires,
D. Pich,
R. Zeidler,
H.-J. Delecluse, and W. Hammerschmidt.
1998.
Activation of the Epstein-Barr virus transcription factor BZLF1 by 12-O-tetradecanoylphorbol-13-acetate-induced phosphorylation.
J. Virol.
72:8105-8114[Abstract/Free Full Text].
|
| 9.
|
Bell, P.,
P. M. Lieberman, and G. G. Maul.
2000.
Lytic but not latent replication of Epstein-Barr virus is associated with PML and induces sequential release of nuclear domain 10 proteins.
J. Virol.
74:11800-11810[Abstract/Free Full Text].
|
| 10.
|
Burkham, J.,
D. M. Coen, and S. K. Weller.
1998.
ND10 protein PML is recruited to herpes simplex virus type 1 prereplicative sites and replication compartments in the presence of viral DNA polymerase.
J. Virol.
72:10100-10107[Abstract/Free Full Text].
|
| 11.
|
Cayrol, C., and E. Flemington.
1996.
G0/G1 growth arrest mediated by a region encompassing the basic leucine zipper (bZIP) domain of the Epstein-Barr virus transactivator Zta.
J. Biol. Chem.
271:31799-31802[Abstract/Free Full Text].
|
| 12.
|
Cayrol, C., and E. K. Flemington.
1996.
The Epstein-Barr virus bZIP transcription factor Zta causes G0/G1 cell cycle arrest through induction of cyclin-dependent kinase inhibitors.
EMBO J.
15:2748-2759[Medline].
|
| 13.
|
Chang, Y.-N.,
D. L.-Y. Dong,
G. S. Hayward, and S. D. Hayward.
1990.
The Epstein-Barr virus Zta transactivator: a member of the bZIP family with unique DNA-binding specificity and a dimerization domain that lacks the characteristic heptad leucine zipper motif.
J. Virol.
64:3358-3369[Abstract/Free Full Text].
|
| 14.
|
Chen, C. J.,
Z. Deng,
A. Y. Kim,
G. A. Blobel, and P. M. Lieberman.
2001.
Stimulation of CREB binding protein nuclecosomal histone acetyltransferase activity by a class of transcriptional activators.
Mol. Cell. Biol.
21:476-487[Abstract/Free Full Text].
|
| 15.
|
Cheng, L., and T. J. Kelly.
1989.
Transcriptional activator nuclear factor I stimulates the replication of SV40 minichromosomes in vivo and in vitro.
Cell
59:541-551[CrossRef][Medline].
|
| 16.
|
Chi, T., and M. Carey.
1993.
The ZEBRA activation domain: modular organization and mechanism of action.
Mol. Cell. Biol.
13:7045-7055[Abstract/Free Full Text].
|
| 17.
|
Chi, T.,
P. Lieberman,
K. Ellwood, and M. Carey.
1995.
A general mechanism for transcriptional synergy by eukaryotic activators.
Nature
377:254-257[Medline].
|
| 18.
|
Crute, J. J.,
T. Tsurumi,
L. Zhu,
S. K. Weller,
P. D. Olivo,
M. D. Challberg,
E. S. Mocarski, and I. R. Lehman.
1989.
Herpes simplex virus 1 helicase-primase: a complex of three herpes-encoded gene products.
Proc. Natl. Acad. Sci. USA
86:2186-2189[Abstract/Free Full Text].
|
| 19.
|
Farrell, P.,
D. Rowe,
C. Rooney, and J. Kouzarides.
1989.
EBV BZLF-1 transactivator specifically binds to consensus AP-1 sites and is related to c-fos.
EMBO J.
8:127-132[Medline].
|
| 20.
|
Fixman, E. D.,
G. S. Hayward, and S. D. Hayward.
1995.
Replication of Epstein-Barr virus oriLyt: lack of a dedicated virally encoded origin-binding protein and dependence on Zta in cotransfection assays.
J. Virol.
69:2998-3006[Abstract].
|
| 21.
|
Flemington, E., and S. H. Speck.
1990.
Evidence for coiled-coil dimer formation by an Epstein-Barr virus transactivator that lacks a heptad repeat of leucine residues.
Proc. Natl. Acad. Sci. USA
87:9459-9463[Abstract/Free Full Text].
|
| 22.
|
Fujii, K.,
N. Yokoyama,
T. Kiyono,
K. Kuzushima,
M. Homma,
Y. Nishiyama,
M. Fujita, and T. Tsurumi.
2000.
The Epstein-Barr virus pol catalytic subunit physically interacts with the BBLF4-BSLF1-BBLF2/3 complex.
J. Virol.
74:2550-2557[Abstract/Free Full Text].
|
| 23.
|
Gao, Z.,
A. Krithivas,
J. E. Finan,
O. J. Semmes,
S. Zhou,
Y. Wang, and S. D. Hayward.
1998.
The EBV lytic transactivator Zta interacts with the helicase-primase replication complex.
J. Virol.
72:8559-8567[Abstract/Free Full Text].
|
| 24.
|
Guo, Z. S.,
C. Gutierrez,
U. Heine,
J. M. Sogo, and M. L. Depamphilis.
1989.
Origin auxiliary sequences can facilitate initiation of simian virus 40 DNA replication in vitro as they do in vivo.
Mol. Cell. Biol.
9:3593-3602[Abstract/Free Full Text].
|
| 25.
|
Hammerschmidt, W., and B. Sugden.
1988.
Identification and characterization of oriLyt, a lytic origin of DNA replication of Epstein-Barr virus.
Cell
55:427-433[CrossRef][Medline].
|
| 26.
|
Hsieh, J. J.-D.,
T. Henkel,
P. Salmon,
E. Robey,
M. G. Peterson, and S. D. Hayward.
1996.
Truncated mammalian Notch1 activates CBF1/RBPJk-repressed genes by a mechanism resembling that of Epstein-Barr virus EBNA2.
Mol. Cell. Biol.
16:952-959[Abstract].
|
| 27.
|
Hu, Y. F.,
Z. L. Hao, and R. Li.
1999.
Chromatin remodeling and activation of chromosomal DNA replication by an acidic transcriptional activation domain from BRCA1.
Genes Dev.
13:637-642[Abstract/Free Full Text].
|
| 28.
|
Ishov, A. M., and G. G. Maul.
1996.
The periphery of nuclear domain 10 (ND10) as site of DNA virus deposition.
J. Cell Biol.
134:815-826[Abstract/Free Full Text].
|
| 29.
|
Kiehl, A., and D. I. Dorsky.
1991.
Cooperation of EBV DNA polymerase and EA-D(BMFR1) in vitro, and colocalization in nuclei of infected cells.
Virology
184:330-340[CrossRef][Medline].
|
| 30.
|
Kolman, J. L.,
N. Taylor,
L. Gradoville,
J. Countryman, and G. Miller.
1996.
Comparing transcriptional activation and autostimulation by ZEBRA and ZEBRA/c-Fos chimeras.
J. Virol.
70:1493-1504[Abstract].
|
| 31.
|
Kolman, J. L.,
N. Taylor,
D. R. Marshak, and G. Miller.
1993.
Serine-173 of the Epstein-Barr virus ZEBRA protein is required for DNA binding and is a target for casein kinase II phosphorylation.
Proc. Natl. Acad. Sci. USA
90:10115-10119[Abstract/Free Full Text].
|
| 32.
|
Korioth, F.,
G. G. Maul,
B. Plachter,
T. Stamminger, and J. Frey.
1996.
The nuclear domain 10 (ND10) is disrupted by the human cytomegalovirus gene product IE1.
Exp. Cell Res.
229:155-158[CrossRef][Medline].
|
| 33.
|
Korzus, E.,
J. Torchia,
D. W. Rose,
L. Xu,
R. Kurokawa,
E. M. McInerney,
T. M. Mullen,
C. K. Glass, and M. G. Rosenfeld.
1998.
Transcription factor-specific requirements for coactivators and their acetyltransferase functions.
Science
279:703-707[Abstract/Free Full Text].
|
| 34.
|
Li, J.-S.,
B.-S. Zhou,
G. E. Dutschman,
S. P. Grill,
R.-S. Tan, and Y.-C. Cheng.
1987.
Association of Epstein-Barr virus early antigen diffuse component and virus-specified DNA polymerase activity.
J. Virol.
61:2947-2949[Abstract/Free Full Text].
|
| 35.
|
Li, R., and M. R. Botchan.
1994.
Acidic transcription factors alleviate nucleosome-mediated repression of DNA replication of bovine papillomavirus type 1.
Proc. Natl. Acad. Sci. USA
91:7051-7055[Abstract/Free Full Text].
|
| 36.
|
Lieberman, P. M., and A. J. Berk.
1990.
In vitro transcriptional activation, dimerization, and DNA-binding specificity of the Epstein-Barr virus Zta protein.
J. Virol.
64:2560-2568[Abstract/Free Full Text].
|
| 37.
|
Lieberman, P. M., and A. J. Berk.
1994.
A mechanism for TAFs in transcriptional activation: activation domain enhancement of TFIID-TFIIA-promoter DNA complex formation.
Genes Dev.
8:995-1006[Abstract/Free Full Text].
|
| 38.
|
Lieberman, P. M.,
J. M. Hardwick,
J. Sample,
G. S. Hayward, and S. D. Hayward.
1990.
The Zta transactivator involved in induction of lytic cycle gene expression in Epstein-Barr virus-infected lymphocytes binds to both AP-1 and ZRE sites in target promoter and enhancer regions.
J. Virol.
64:1143-1155[Abstract/Free Full Text].
|
| 39.
|
Lieberman, P. M.,
P. O'Hare,
G. S. Hayward, and S. D. Hayward.
1986.
Promiscuous trans-activation of gene expression by an Epstein-Barr virus-encoded early nuclear protein.
J. Virol.
60:140-148[Abstract/Free Full Text].
|
| 40.
|
Lieberman, P. M.,
J. Ozer, and D. B. Gursel.
1997.
Requirement for transcription factor IIA (TDFIIA)-TFIID recruitment by an activator depends on promoter structure and template competition.
Mol. Cell. Biol.
17:6624-6632[Abstract].
|
| 41.
|
Lukonis, C. J.,
J. Burkham, and S. K. Weller.
1997.
Herpes simplex virus type 1 prereplicative sites are a heterogeneous population: only a subset are likely to be precursors to replication compartments.
J. Virol.
71:4771-4781[Abstract].
|
| 42.
|
Maul, G. G.
1998.
Nuclear domain 10, the site of DNA virus transcription and replication.
Bioessays
20:660-667[CrossRef][Medline].
|
| 43.
|
Maul, G. G.,
H. H. Guldner, and J. G. Spivack.
1993.
Modification of discrete nuclear domains induced by herpes simplex virus type 1 immediate early gene 1 product (ICP0).
J. Gen. Virol.
74:2679-2690[Abstract/Free Full Text].
|
| 44.
|
Muller, K., and N. Mermod.
2000.
The histone-interacting domain of nuclear factor I activates simian virus 40 DNA replication in vivo.
J. Biol. Chem.
275:1645-1650[Abstract/Free Full Text].
|
| 45.
|
Nguyen-Huynh, A. T., and P. A. Schaffer.
1998.
Cellular transcription factors enhance herpes simplex virus type 1 oriS-dependent DNA replication.
J. Virol.
72:3635-3645[Abstract/Free Full Text].
|
| 46.
|
Ogryzko, V. V.,
R. L. Shiltz,
V. Russanova,
B. H. Howard, and Y. Nakatini.
1996.
The transcriptional coactivators p300 and CBP are histone acetyltransferases.
Cell
87:953-959[CrossRef][Medline].
|
| 47.
|
Portes-Sentis, S.,
A. Sergeant, and H. Gruffat.
1997.
A particular DNA structure is required for the function of a cis-acting component of the Epstein-Barr virus OriLyt origin of replication.
Nucleic Acids Res.
25:1347-1354[Abstract/Free Full Text].
|
| 48.
|
Ptashne, M., and A. Gann.
1997.
Transcriptional activation by recruitment.
Nature
386:569-577[CrossRef][Medline].
|
| 49.
|
Rodrigiuez, A.,
M. Armstrong,
D. Dwyer, and E. Flemington.
1999.
Genetic dissection of cell growth arrest functions mediated by the Epstein-Barr virus lytic gene product, Zta.
J. Virol.
73:9029-9038[Abstract/Free Full Text].
|
| 50.
|
Ryon, J. J.,
E. D. Fixman,
C. Houchens,
J. Zong,
P. M. Lieberman,
Y.-N. Chang,
G. S. Hayward, and S. D. Hayward.
1993.
The lytic origin of herpesvirus papio is highly homologous to Epstein-Barr virus ori-Lyt: evolutionary conservation of transcriptional activation and replication signals.
J. Virol.
67:4006-4016[Abstract/Free Full Text].
|
| 51.
|
Sarisky, R. T.,
Z. Gao,
P. M. Lieberman,
E. D. Fixman,
G. S. Hayward, and S. D. Hayward.
1996.
A replication function associated with the activation domain of the Epstein-Barr virus Zta transactivator.
J. Virol.
70:8340-8347[Abstract].
|
| 52.
|
Sarisky, R. T., and G. S. Hayward.
1996.
Evidence that the UL84 gene product of human cytomegalovirus is essential for promoting oriLyt-dependent DNA replication and formation of replication compartments in cotransfection assays.
J. Virol.
70:7398-7413[Abstract].
|
| 53.
|
Schepers, A.,
D. Pich, and W. Hammerschmidt.
1996.
Activation of orilyt, the lytic origin of DNA replication of Epstein-Barr virus, by BZLF1.
Virology
220:367-376[CrossRef][Medline].
|
| 54.
|
Schepers, A.,
D. Pich,
J. Mankertz, and W. Hammerschmidt.
1993.
cis-acting elements in the lytic origin of DNA replication of Epstein-Barr virus.
J. Virol.
67:4237-4245[Abstract/Free Full Text].
|
| 55.
|
Takagi, S.,
K. Takad, and T. Sairenji.
1991.
Formation of intranuclear replication compartments of Epstein-Barr virus with redistribution of BZLF1 and BMRF1 gene products.
Virology
185:309-315[CrossRef][Medline].
|
| 56.
|
Tang, Q.,
P. Bell,
P. Tegtmeyer, and G. G. Maul.
2000.
Replication but not transcription of simian virus 40 DNA is dependent on nuclear domain 10.
J. Virol.
74:9694-9700[Abstract/Free Full Text].
|
| 57.
|
Taylor, N.,
E. Flemington,
J. L. Kolman,
R. P. Baumann,
S. H. Speck, and G. Miller.
1991.
ZEBRA and a Fos-GCN4 chimeric protein differ in their DNA-binding specificities for sites in the Epstein-Barr virus BZLF1 promoter.
J. Virol.
65:4033-4041[Abstract/Free Full Text].
|
| 58.
|
Uprichard, S. L., and D. M. Knipe.
1997.
Assembly of herpes simplex virus replication proteins at two distinct intranuclear sites.
Virology.
229:113-125[CrossRef][Medline].
|
| 59.
|
Wu, F. Y.,
J. H. Ahn,
D. J. Alcendor,
W. J. Jang,
J. Xiao,
S. D. Hayward, and G. S. Hayward.
2001.
Origin-independent assembly of Kaposi's sarcoma-associated herpesvirus DNA replication compartments in transient cotransfection assays and association with the ORF-K8 protein and cellular PML.
J. Virol.
75:1487-1506[Abstract/Free Full Text].
|
| 60.
|
Yokoyama, N.,
K. Fujii,
M. Hirata,
K. Tamai,
T. Kiyono,
K. Kuzushima,
Y. Nishiyama,
M. Fujita, and T. Tsurumi.
1999.
Assembly of the Epstein-Barr virus BBLF4, BSLF1 and BBLF2/3 proteins and their interactive properties.
J. Gen. Virol.
80:2879-2887[Abstract/Free Full Text].
|
| 61.
|
Zeng, Y.,
J. Middeldorp,
J. J. Madjar, and T. Ooka.
1997.
A major DNA binding protein encoded by BALF2 open reading frame of Epstein-Barr virus (EBV) forms a complex with other EBV DNA-binding proteins: DNase, EA-D, and DNA polymerase.
Virology
239:285-295[CrossRef][Medline].
|
| 62.
|
Zerby, D.,
C.-J. Chen,
E. Poon,
R. Shiekhattar, and P. M. Lieberman.
1999.
The amino-terminal C/H1 domain of CREB binding protein mediates Zta transcriptional activation of latent Epstein-Barr virus.
Mol. Cell. Biol.
19:1617-1626[Abstract/Free Full Text].
|
| 63.
|
Zhang, Q.,
E. Holley-Guthrie,
D. Dorsky, and S. Kenney.
1999.
Identification of transactivator and nuclear localization domains in the Epstein-Barr virus DNA polymerase accessory protein, BMRF1.
J. Gen. Virol.
80:69-74[Abstract].
|
| 64.
|
Zhang, Q.,
E. Holley-Guthrie,
J. Q. Ge,
D. Dorsky, and S. Kenney.
1997.
The Epstein-Barr virus (EBV) DNA polymerase accessory protein, BMRF1, activates the essential downstream component of the EBV oriLyt.
Virology
230:22-34[CrossRef][Medline].
|
| 65.
|
Zhang, Q.,
Y. Hong,
D. Dorsky,
E. Holley-Guthrie,
S. Zalani,
N. A. Elshiekh,
A. Kiehl,
T. Le, and S. Kenney.
1996.
Functional and physical interactions between the Epstein-Barr virus (EBV) proteins BZLF1 and BMRF1: effects on EBV transcription and lytic replication.
J. Virol.
70:5131-5142[Abstract/Free Full Text].
|
| 66.
|
Zhong, L., and G. S. Hayward.
1997.
Assembly of complete, functionally active herpes simplex virus DNA replication compartments and recruitment of associated viral and cellular proteins in transient cotransfection assays.
J. Virol.
71:3146-3160[Abstract].
|